Post-marketing requirements for FDA PMRs, PMCs and study status
FDA post-marketing requirements are studies sponsors must run by law. Commitments are agreed studies. Statuses show whether tracked work is still open.
Post-marketing requirements at FDA for PMRs, PMCs and study status
FDA post-marketing requirements (PMRs) are studies and clinical trials that a drug or biologic sponsor must conduct because a statute or regulation requires them. Postmarketing commitments (PMCs) are studies or trials the sponsor agrees to conduct that no statute or regulation requires (FDA).
Both kinds of post-marketing study collect more information about a product's safety, efficacy or optimal use (FDA). The distinction is the legal basis for doing the work. A confirmatory trial for accelerated approval can begin before approval. Scope here is those studies for US drugs and biologics, not device post-market surveillance or EU post-market surveillance requirements.
Requirements versus commitments
The requirement to conduct a PMR comes from a statute or regulation (FDA). A PMC's agreed basis does not remove reporting duties. For NDAs, the annual-report rule covers certain studies the applicant has committed in writing to conduct, as well as required studies (21 CFR 314.81(b)(2)(vii)).
Older FDA documents need careful reading. FDA historically used the word "commitment" for both mandatory and agreed studies, so an older document that says "commitment" may be describing what is now called a requirement (FDA).
The legal bases for post-marketing requirements
Not every PMR is a safety study, and not every PMR comes from the same section of law. FDA identifies four main categories (FDA):
| Category | What the required work does |
|---|---|
| FDAAA, FD&C Act section 505(o)(3) | Safety studies or trials to assess a known serious risk, assess signals of serious risk, or identify an unexpected serious risk when available data indicate the potential for a serious risk |
| Accelerated approval | Studies or trials to demonstrate clinical benefit, under 21 CFR 314.510 and 601.41 |
| Pediatric Research Equity Act (PREA) | Deferred pediatric studies, under 21 CFR 314.55(b) and 601.27(b) |
| Animal Efficacy Rule | Studies to show safety and efficacy in humans at the time of use, for products approved under this pathway |
The three serious-risk purposes for section 505(o)(3) describe what those studies are for. They are not the complete statutory test for imposing a requirement, so read the statute before using the list as a checklist. PREA PMRs are deferred pediatric studies, and not every pediatric study is a PMR.
Confirmatory trials do not always start after approval
The word "postmarketing" describes the purpose of the study, not when it begins. The Consolidated Appropriations Act, 2023 amended FD&C Act section 506(c) so that FDA can require confirmatory studies for accelerated approval to be underway before approval or within a specified period after it, as appropriate (FDA).
FDA explains its thinking in a January 2025 draft guidance on when a confirmatory trial counts as underway. That document is marked as a draft, not for implementation, and nonbinding. The authority comes from the statute, not the draft (FDA). Before you rely on it, check whether FDA has issued a later version.
For an accelerated approval product, check the applicable reporting rules separately. Do not use the NDA annual-report section below as a complete compliance checklist.
What FDA's study statuses mean
FDA uses seven status terms for the studies it tracks. Five statuses are open and two are closed (FDA FAQ, question 20):
| Status | Meaning | Open or closed |
|---|---|---|
| Pending | Not started, but not delayed, because the original projected start date has not passed | Open |
| Ongoing | On or ahead of the original schedule; can remain ongoing until the final report is submitted | Open |
| Delayed | Behind the original schedule, not a revised one. The delay can be in enrollment, analysis or final report submission | Open |
| Terminated | Ended before completion, with no final report submitted yet | Open |
| Submitted | Completed or terminated, and the final report is submitted, but FDA has not yet sent written notice of fulfillment or release | Open |
| Fulfilled | FDA reviewed the final report and is satisfied the terms were met | Closed |
| Released | FDA told the applicant the obligation is released because the study is no longer feasible or would no longer give useful information | Closed |
Do not treat "Submitted" as closed. Sending the final report does not close the obligation. Only FDA's written fulfillment or release does. "Terminated" is also an open status, not a closed one. "Released" does not mean the study succeeded. It means FDA released the requirement or commitment for the reasons in the table.
"Delayed" is measured against the original schedule, not a revised schedule. If a later phase gets back on schedule, the delayed status no longer applies. If patient accrual or animal dosing has started but is not complete, and the projected date for that milestone has passed, FDA says to categorize the study as delayed (FDA FAQ).
Annual status reports
For NDAs, the annual report under 21 CFR 314.81(b)(2) is due within 60 days of the anniversary of the US approval of the application. FDA's FAQ (question 8) explains that the original application approval date sets this anniversary, and supplements do not need separate annual reports (FDA FAQ). The 60 days do not run from each study milestone or from each supplement's approval.
Section 314.81(b)(2)(vii) asks for status reports on required studies and on written commitments for studies of clinical safety, clinical efficacy, clinical pharmacology or nonclinical toxicology. The report describes each study, its schedule and an explanation of its status (eCFR).
Status reporting continues until FDA sends written notice that the study is fulfilled or released, not just until you submit the final report (FDA FAQ). This section covers the NDA annual-report rule, not every reporting duty. Check the provisions that apply to your application.
How to search the FDA PMR/PMC database
FDA publishes a Postmarketing Requirements and Commitments: Searchable Database. Open the landing page and use its "Search the Database" link.
FDA's FAQ (question 11) lists optional search filters (FDA FAQ):
- center
- applicant
- product or active ingredient
- full NDA, ANDA or BLA number, entered without a hyphen
- status
- requirement authority
- approval date range
A practical approach is to start with the product or active ingredient, or with the full application number if you have it. Then narrow by applicant or by requirement authority if the results are broad, and read each status using the definitions above.
What the database does not show
The public database is neither live nor complete. Treat it as FDA's published view of tracked studies, not a full register of every obligation on a product.
- It updates quarterly, on or around the end of January, April, July and October (FDA). Publishing of annual-report information can lag, depending on when the report was submitted and when FDA verifies it (FDA FAQ). An entry that looks out of date does not on its own show that a sponsor is out of compliance.
- It includes PMRs and section 506B PMCs, which FDA describes as studies and trials for clinical safety, clinical efficacy, clinical pharmacology and nonclinical toxicology. It includes all open PMRs and 506B PMCs, and only closed records fulfilled or released within the last year (FDA). If an older fulfilled study is missing, that does not mean it never existed.
- Proprietary commitments are excluded, including those on chemistry, manufacturing and controls (FDA). If a product does not appear, that does not prove it has no post-marketing obligations.
RegAffairs AI provides a cited answer on FDA postmarketing requirements, commitments and study status.